In various embodiments, the present disclosure provides methods reducing the risk of a cardiovascular event in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof by increasing the subject's plasma and serum EPA levels.